beta

MYL

Mylan NV

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Market Cap: 8.42 Billion

Primary Exchange: NASDAQ

Website: http://mylan.co.uk

Shares Outstanding: 542 Million

Float: 538 Million

Dividend: (%)

Beta: 0.757108445873012

Sector: Health Technology

Industry: Pharmaceuticals: Generic

Ethical Flags

Longest drawdown: 1559 trading days

From: 2015-04-24 To: 2020-11-13

Lowest Point:

Healthcare Stocks: Invest In Business, Not Science

via: SeekingAlpha at 2019-06-13 02:35:46:000

By Vinay Thapar Healthcare stocks served as powerful painkillers during last year's market declines. Yet the sector offers much more than just downside protection for investors who focus on business potential and resist the urge to predict scientific breakthroughs. While the MSCI World I… read more...

Teva hits 19-year low on continued pricing pressure

via: SeekingAlpha at 2019-06-12 06:49:59:000

Teva Pharmaceutical Industries ( TEVA -4.2% ) slumps on modestly higher volume. Shares are now exchanging hands at the lowest prices in 19 years. The stock continues to fight pricing headwinds, the continued erosion of Copaxone sales (down 56% in Q1) and its potential exposure from opioid … read more...

BIIB Is For Buy-O-Gen

via: SeekingAlpha at 2019-06-12 06:30:36:000

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update

via: SeekingAlpha at 2019-06-12 01:06:09:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud